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pn past years, a January submission date of this yearly review
eries required a Medline search covering the first 10
onths supplemented by a late December manual review of
elected print journals to include all important cardiovascu-
ar surgery articles published during the entire calendar year.
mportant cardiac surgical literature seems to be concen-
rated in relatively few journals, which are all now available
nline (Table 1). Therefore, the Medline search has been
eplaced this year by a more efficient process of scanning the
ables of contents of all journals used as information sources
or the past 4 years. Only articles judged to be of broad
eneral interest to most cardiovascular specialists were
elected. Therefore, a large body of information about how
o best do cardiac surgery has been purposefully omitted.
igh-interest articles with major methodologic flaws were
ncluded in prior years along with a critique cautioning
eaders about weak methodology. High-profile but fatally
awed reports are simply omitted from the calendar year
006 summary, thereby decreasing the methodologic detail
ecessary to include for all articles. In general, the order of
opics and articles described under subtopics reflect the
trength and scope of impact of individual articles reported.
herefore, the first article, “Left Ventricular Assist Device
nd Drug Therapy for the Reversal of Heart Failure,” is
onored as the best cardiovascular surgical article of the
ear.
urgery for Heart Failure
urgery for Nonischemic Cardiomyopathy
ecovery of left ventricular function on left ventricular
ssist device (LVAD). The Best Cardiac Surgical Paper of
006 Award goes to the investigators of the Royal Bromp-
on and Harefield National Health Service Trust for tena-
ious application of scientific thought and energy to a
linical problem often considered futile without access to a
onor heart (1).
Between December 1999 and July 2001, 27 patients
nderwent LVAD insertion at Harefield Hospital for severe
rom the Department of Surgery/Duke Clinical Research Institute, Duke University
edical Center, Durham, North Carolina. Dr. Jones is the principal investigator of
he National Institutes of Health-sponsored Surgical Treatment for Ischemic Heart
ailure (STICH) trial and received no support for production of this article.m
Manuscript received January 11, 2007; revised manuscript received January 19,
007, accepted January 22, 2007.eart failure and low cardiac output evidenced by organ
ysfunction. Exclusions to form a subgroup for this study
ere 3 patients with ischemic cardiomyopathy, 5 patients
ho never could be stabilized on LVAD support, and 4
atients who did not complete the first stage of pharmaco-
ogic therapy. Included patients were those who first toler-
ted maximum titrated doses of lisinopril (40 mg daily),
arvedilol (50 mg twice daily), spironolactone (25 mg daily),
nd losartan (100 mg daily). These 15 remaining patients
ith severe heart failure caused by nonischemic cardiomy-
pathy also completed a second stage of pharmacologic
herapy instituted after the left ventricular diastolic diameter
ad remained constant for 2 weeks. Carvedilol was replaced
y bisoprolol, and clenbuterol was administered in an initial
ose of 40 g twice daily, then at a dose of 40 g 3 times
aily, and finally at a dose of 700 g 3 times daily. After the
VAD could be safely stopped temporarily, 6-min walk
ests were performed. Criteria to be met while the LVAD
as off for 15 min used to consider explantation included: 1)
eft ventricular end-diastolic diameter 60 mm; 2) left
entricular end-systolic diameter 50 mm; 3) left ventric-
lar ejection fraction 45%; 4) left ventricular end-diastolic
ressure 12 mm Hg; 5) resting cardiac index 2.8
/min/m2; and 6) maximal oxygen consumption with exer-
ise of more than 16 ml/kg body weight/min and an
ncrease in minute ventilation consistent with production of
arbon dioxide 34.
Four patients did not meet explantation criteria and
eceived heart transplantation, and 3 of these survived the
erioperative period. After a mean LVAD support duration
f 320  186 days (range 63 to 603 days), 11 (73%) of the
5 patients completed the full course of combination ther-
py and met the explantation criteria. Their mean ejection
raction was 64  8% before explantation as compared with
2  6% before implantation (p  0.001). The mean left
entricular end-diastolic diameter was 55.9  8.3 mm as
ompared with 75.1 16.3 mm (p 0.002). The mean left
entricular end-systolic diameter was 39.6  6.5 mm as
ompared with 66.9  16.3 mm (p  0.002). The 6-min
alk, maximal oxygen consumption, minute ventilation,
nd carbon dioxide production slope, right atrial pressure,
ulmonary-capillary wedge pressure, cardiac output, and
ulmonary artery oxygen saturation all improved. At a
inimum of 4 years follow-up, 8 (73%) of the 11 explan-
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Year in Cardiovascular Surgery May 8, 2007:1887–98ation patients were surviving free of heart transplant and
eart failure symptoms.
urgery for Ischemic Cardiomyopathy
urgical ventricular reconstruction (SVR) outcomes. Be-
ore joining the STICH (Surgical Treatment for Ischemic
eart Failure) trial, a single center conducted a retrospective
eview and 85 of the 122 patients undergoing SVR between
991 and 2003 who would have the STICH hypothesis 2
ntry criteria (2). These criteria include an ejection fraction
0.35, coronary artery disease (CAD) amenable to coronary
rtery bypass grafting (CABG) and dominant akinesia or
yskinesia of the anterior wall. Eighty-two (96.5%) of these
5 patients underwent CABG, and 16 (18.8%) of the 85
atients had mitral valve surgery. Hospital mortality was
.1%. The 79 patients discharged were followed up for a
ean of 43.7 months, during which 14 patients died after a
ean interval of 24.3 months. Survival rates after 1, 3, 5, and
0 years were 89%, 79%, 75%, and 75%, respectively. The left
entricular equatorial diastolic diameter of 70 mm was the
ominant predictor of long-term mortality in a multivariable
odel. Moreover, patients whose anterior dysfunction was
kinesia and not dyskinesia also had significantly poorer long-
erm survival. Postoperatively, all parameters of left ventricular
olume and function improved compared with baseline.
At a second center, 190 (86%) of 220 consecutive patients
ho underwent SVR were alive 2.3 years after surgery and
ost had fewer heart failure symptoms (3). Over 10 years at a
hird institution, 89 patients with a left ventricular ejection
raction ranging from 0.08 to 0.45 underwent SVR with 3.4%
perative mortality and a 5-year survival rate of 82% (4).
The SVR operation was shown to have a much higher
erioperative mortality and morbidity on review of clinical
ata entered into the Society of Thoracic Surgeons’ Na-
ional Database from January 2002 to June 2004 (5).
ources of 132 References in the Yearn Cardiovascular Su gery 2004 to 2007
Table 1 Sources of 132 References in the Yearin Cardiovascular Surgery 2004 to 2007
Journal No. of Citations
Annals of Thoracic Surgery 28
Journal of the American College of Cardiology 25
Circulation 24
Journal of Thoracic and Cardiovascular Surgery 24
Journal of the American Medical Association 7
New England Journal of Medicine 7
American Heart Journal 3
European Journal of Cardiothoracic Surgery 3
Archives of Internal Medicine 2
Canadian Journal of Cardiology 2
European Heart Journal 2
American Journal of Medicine 1
Anesthesiology 1
Journal of Vascular Surgery 1
Lancet 1
Medical Care 1i
Total 132perative mortality was 9.3% in 731 patients undergoing
VR at 141 centers. Re-operation was required in 14.1%.
eath or major complications occurred in 33.5%. Only 20
14%) of these 141 hospitals performed 10 or more SVR
rocedures. Operative mortality and morbidity was greatest
n patients operated on in centers with a 5 procedure total
olume. Multivariable modeling showed nonelective status
o be the strongest predictor of operative mortality among
he 9 significant clinical variables (Table 2). The volume of
rocedures performed at the site was not an independent
redictor of clinical outcomes. This extremely high opera-
ive mortality and morbidity may simply reflect cardiac
urgeons’ commitment to try all possible remedies for
atients who cannot be weaned from cardiopulmonary
ypass. An SVR would be reasonable to perform after
ABG in any patient with anterior myocardial scar who
ould not be weaned from mechanical support after CABG
ecause of left ventricular dysfunction.
No prospective observational studies exist that assess the
otential benefit of adding SVR to CABG in patients with
egional dysfunction. Until definitive information from the
,000 patients randomized in the STICH trial to undergo
ABG with or without SVR is available in 2008, there is no
ompelling reason to perform elective SVR.
urgery for Ischemic Heart Disease
omparison of CABG With
lternate Treatment Strategies
onfidential recording of treatment preference enhances
alue of randomized trial results. The MASS II (Medi-
ine, Angioplasty, or Surgery Study II) randomized 611
atients with stable multivessel CAD with 70% stenotic
esions amenable to percutaneous coronary intervention
PCI) and preserved left ventricular function among 3
reatment options of medical therapy only (n  203),
evascularization by PCI (n  205), or CABG (n  203)
6). The randomization date was regarded as the time
reatment began, and analysis was by intention to treat.
owever, before randomization, a confidential preferred
reatment decision representing the consensus of 2 experi-
nced noninterventional cardiologists was recorded. Figure
compares the primary combined 1-year end point of survival
ree of death, myocardial infarction (MI), or recurrent ischemia
equiring revascularization for each of the 3 randomized
ohorts stratified by concordance or discordance between the
reatment preferred by the clinicians and the treatment as-
igned by randomization. Percutaneous coronary intervention
as the only treatment for which the clinically defined pre-
erred treatment was sufficiently discordant from the random-
zed treatment assignment to make a significant difference in
he primary end point (Fig. 2). A multivariable logistic regres-
ion model developed to identify baseline characteristics that
nfluenced the clinical treatment preference decision showed
he number of diseased coronary arteries to be the only
ndependent predictor of discordant status. The presence of
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May 8, 2007:1887–98 Year in Cardiovascular Surgery-vessel CAD decreased the odds for a PCI treatment decision
y more than 2-fold. Therefore, in a care setting outside the
andomized trial, these experienced noninterventional cardiol-
gists would have chosen PCI for fewer patients, and those
hey referred to PCI would be expected to have a more
vent-free outcome than the PCI cohort actually experienced
y random treatment assignment to PCI.
Percutaneous coronary intervention had more events that
ere dominated by need for subsequent revascularization
hen analyzed by randomization treatment assigned. With-
ut subsequent secondary testing of their preferred treat-
ent allocation, the published trial results might have
onvinced the 2 clinicians that their hesitancy about PCI use
n patients with 3-vessel CAD was unwarranted bias and
ot reflective of superior clinical judgment.
Figure 1 Influence of Mode of
Treatment Selection on Outcome
This 3  3 table of 1-year probabilities of event-free survival for the 9 possibili-
ties of concordant (white boxes) and discordant (blue boxes) interactions
among the 3 treatments shows discordance to have the greatest negative
effect in the population randomized to percutaneous coronary intervention (PCI)
and the least effect on the population randomized to coronary artery bypass
graft (CABG). Reprinted with permission from Pereira et al. (6).
redictors of SVR Operative Mortality and Morbidity
Table 2 Predictors of SVR Operative Mortality and Morbidity
Characteristic
Adjusted OR
(95% CI) p Value
Status (urgent/emergent/salvage vs. elective) 2.02 (1.44–2.83) 0.001
3-vessel coronary disease 1.78 (1.25–2.55) 0.002
Insulin-dependent diabetes 1.85 (1.17–2.94) 0.009
MI 1 week 1.81 (1.16–2.83) 0.010
Gender (female vs. male) 1.61 (1.11–2.32) 0.011
Creatinine, 2 mg/dl 2.51 (1.22–5.18) 0.015
Severe mitral insufficiency 1.80 (1.11–2.91) 0.017
Age (per 10-yr increase) 1.18 (1.02–1.38) 0.029
History of congestive heart failure 1.45 (1.02–2.06) 0.037
eprinted with permission from Hernandez et al. (5).
CI confidence interval; MImyocardial infarction; OR odds ratio; SVR surgical ventricular
econstruction.cPrior randomized trials have attempted to document
eneralizability of results observed in a randomized cohort
o a broader population by comparing baseline characteris-
ics of registry with randomized patients. However, this
pproach is costly, and even if baseline demographic and
Figure 2 Concordance of Treatment Assignment Alters
Observed Benefit Only for Patients Randomized to PCI
Kaplan-Meier curves stratified by concordance (green lines) and discordance
(black lines) for (A) all patients randomized to PCI, (B) all patients randomized to
CABG, and (C) all patients randomized to medical treatment show significant dif-
ferences in the PCI randomized cohort for whom the outcome of this treatment
was better if it was in concordance with the preferred treatment of clinicians.
Abbreviations as in Figure 1. Reprinted with permission from Pereira et al. (6).linical characteristics assessed are similar, the diverse rea-
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Year in Cardiovascular Surgery May 8, 2007:1887–98ons patients or their physicians make a choice against
andomization introduce bias and confounding. Experi-
nced clinicians at equipoise to randomize a patient for
hom definitive evidence does not exist for benefit between
lternate treatment strategies can readily record a treatment
reference they do not consider to be evidence-based.
omparison of outcomes between the randomized and
linically preferred treatment assignments would confirm
he generalizability of the randomized result in 2 settings.
o difference in treatment effectiveness between concordant
r discordant groupings or discordant differences that show
he randomized assignment to be more effective than the
referred clinical treatment would confirm broad generaliz-
bility of the randomized study outcome. This comparison
n MASS II suggests that a patient cohort selected with
ewer patients with severe 3-vessel CAD would have had
ewer events. Therefore, PCI would have had outcomes
ore similar to the other 2 treatments if the criteria the
linicians used to make their preferred treatment selection
lso had been entry criteria for randomization.
rospective 17-year observational study of medical therapy,
CI, and CABG. An institutional database was the
esource used to compare long-term outcomes of medical
herapy with revascularization and CABG to PCI as the
ode of revascularization (7). A total of 18,481 patients
ere followed up annually for survival during a mean 7.4
ears and maximal 17-year follow-up. Percutaneous cor-
nary intervention or CABG within 30 days of cardiac
atheterization defined the 2 revascularization subgroups
or analysis, and the remaining patients formed the
edical treatment group. To avoid bias associated with
arly deaths before patients could undergo revasculariza-
ion, all patients were excluded from the study that died
ithout a revascularization procedure within 5 days
defined by the median CABG waiting time). Cox
ultivariable modeling identified only 8 major baseline
ariables contained 94% of the information predictive of
ong-term death (Table 3). Models examining interac-
ox Model Predicting Death in 18,481uke Patients Followed Up for 7.4 YearsMean) After Catheterization Evaluationor CABG, PCI, or M dical Therapy of CAD
Table 3
Cox Model Predicting Death in 18,481
Duke Patients Followed Up for 7.4 Years
(Mean) After Catheterization Evaluation
for CABG, PCI, or Medical Therapy of CAD
Variable % Information Hazards Ratio Magnitude
Age 39 1.66 10 yrs
Ejection fraction 16 0.85 0.05
Diabetes 10 1.63 All forms
CAD index* 8 1.30 10 U
Vascular index 6 1.30 Peripheral or cerebral
Body mass index 6 0.92 25 kg/m2
Heart failure 3 1.14 Ongoing
Noncardiac 6
Other cardiac 6
Total 100
Strong interaction with treatment choice. Adapted with permission from Smith et al. (7).t
CABG  coronary artery bypass graft; CAD  coronary artery disease; PCI  percutaneous
oronary intervention.ions with treatment choice identified the Duke CAD
ndex to be the only variable to interact independently
ith treatment. The low-severity group included patients
ith 1- or 2-vessel CAD 75%, but none with stenoses
95%. This group had a significant survival benefit with
CI. The high-severity group was characterized by
-vessel CAD 75% and 2- or 3-vessel CAD 95%.
his coronary anatomy identified patients with a survival
enefit from CABG. The intermediate-severity group
ad equivalent survival with PCI and CABG.
Separate Kaplan-Meier curves adjusted for baseline clin-
cal characteristics and propensity for a specific treatment
nd stratified by CAD severity were created for patients
eceiving medical therapy and revascularization by either
CI or CABG. A plot of survival differences between
atients treated with the 2 treatment strategies showed
evascularization to increase survival for all levels of CAD
everity over the 17 years of follow-up (Fig. 3). However,
his medical cohort included only patients whose clinical
ymptomatology or noninvasive test evaluation suggested a
eed for coronary angiography. Moreover, the medical
herapy that many patients received during the early years of
he enrollment interval spanning 1986 to 2000 would now
e considered suboptimal.
Subtraction of the PCI from the CABG risk-adjusted
aplan-Meier survival curves for the high-severity CAD
roup showed a CABG survival advantage of about 6
atients per 100 treated during years 4 to 12 of follow-up
Fig. 4). The intermediate-severity and low-severity groups
id not show significant differences over time. Figure 5
epicts additional months of survival over 15 years added by
evascularization compared with medical therapy. Revascu-
arizations by either method added significant survival time
t all CAD levels. Comparisons of choice of revasculariza-
ion strategy showed a clear survival difference favoring
ABG over PCI in the high-severity CAD group. How-
ver, both CABG and PCI add similar survival benefit over
edical therapy to patients with low-severity and
ntermediate-severity CAD. This information used in the
ontext of the clinical status and life situation adds quanti-
ation of anticipated benefit of alternate treatment strategies
or individual patients.
edside estimation of PCI and CABG procedure risk.
eparate multivariable logistic regression models developed
rom 46,060 PCI procedures (8) and 16,120 CABG proce-
ures (9) performed in New York State during 2002 were
implified into a risk index that, when applied to all 2003
ata, performed with a C-index of 0.905 for PCI and 0.782
or CABG. These indices can be applied to estimate the
evascularization procedure mortality for an individual pa-
ient or defined patient cohort. Moreover, these scores also
ere shown to relate to procedure morbidity and length of
tay in New York. Clear criteria for scoring baseline clinical
nformation needed to calculate total PCI and CABG risk
cores (Table 4) are converted to actual predicted mortality
hat would have been expected should the patient have been
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May 8, 2007:1887–98 Year in Cardiovascular Surgeryreated in 2003 in New York (Tables 5 and 6). These
redicted mortality data may simply be described to patients
uring the informed consent process. Alternatively, the ratio
f actual procedure mortality in any patient cohort to the
bserved 2003 New York State CABG mortality (1.61%) or
CI mortality (0.58%) can be used to recalibrate the score to
eflect mortality rates expected for a patient or patient
ohort in local care environments. Cardiac surgeons and
ardiologists who now do not regularly monitor their
evascularization procedure outcomes now have a no-
echnology, easy-to-use tool to monitor success of their
uality improvement programs and thereby bring ongoing
uantitation of outcomes to their practice.
utcomes of CABG within 6 h of PCI. The Society of
horacic Surgeons’ National Cardiac Surgery Database was
sed to examine the 1994 to 2003 incidence and outcomes
f patients undergoing CABG within 6 h of PCI (10).
atients were stratified into groups based on whether an MI
ad occurred within 24 h of PCI. The database did not
ermit further timing of the occurrence of the MI relative to
ntervals before, during, or after PCI. The CABG proce-
ures done emergently after PCI decreased from 2.9% in
994 to 0.8% in 1999 of the total CABG operations. The
ubset sustaining acute MI within 24 h of CABG decreased
Figure 3 Survival Benefit for Revascularization Versus Medical
Kaplan-Meier curves adjusted by Cox analysis for baseline clinical differences and
created for the medically treated cohort and a combined revascularization cohort t
ing revascularization curves, and their differences were plotted over the 17-year fo
100 who survived with revascularization who would not have survived if treated wit
et al. (7).ess dramatically over this interval and stabilized in 1999 at (.3% of the total CABG population (Fig. 6). Although
everity of baseline predictors of operative risk increased as the
umbers of total patients undergoing CABG decreased over
he 10-year interval, risk-adjusted CABG operative mortality
nd combined morbidity remained stable. Operative death
ccurred in 6% of patients presenting for operation with noMI
nd in 15% of patients with a preoperative MI. Combined
ortality and morbidity rates were above 20% for patients with
o MI and averaged 40% in patients with MI (Fig. 7).
herefore, the need for urgent CABG after PCI is decreasing,
ut this event continues to impose substantial mortality and
orbidity to the CABG population.
trategies for Optimizing CABG Outcomes
ositron emission tomography (PET) myocardial
erfusion and viability assessment does not discriminate
atients who need revascularization. The value of quan-
itative PET fluorodeoxyglucose (FDG) imaging of myo-
ardial perfusion and viability for identifying patients that
eceive a survival benefit from revascularization was assessed
n 765 consecutive patients with ejection fraction0.35 and
ithout significant valvular heart disease (11). Within the
rst 6 months of study entry between 1997 and 2002, 230
py by CAD Severity
nsity for treatment and stratified by coronary artery disease (CAD) severity were
by PCI or CABG. The 3 medical curves were subtracted from the 3 correspond-
interval. The absolute percent difference over time depicts the patients out of
ical therapy. Abbreviations as in Figure 1. Adapted with permission from SmithThera
prope
reated
llow-up
h med30%) of the 765 patients underwent early surgical (25%) or
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Year in Cardiovascular Surgery May 8, 2007:1887–98CI (5%) intervention. Seventy percent of patients without
arly intervention were considered to be medically treated,
nd death occurred in 184 (34.7%) of these 535 patients.
aseline, demographic, clinical, and PET/FDG variables
ere used to propensity match 153 of the 230 early
ntervention patients with 153 patients who did not undergo
arly intervention. In this propensity-matched cohort of 306
atients, there were 84 deaths (27.5% mortality) during a
edian of 3 years of follow-up. In the early intervention
ohort of 153 patients, CABG with or without valve surgery
as performed in 113, PCI was used in 30, and another
pen heart surgery was done in 10. Early intervention was
ssociated with an adjusted 3-year mortality hazard ratio of
.52, 95% confidence interval 0.33 to 0.81, p  0.0004. The
mount of total combined ischemia and hibernation tended to
redict mortality, but early intervention was associated with a
ower risk of death across the full range of ischemia and
ibernation. Therefore, careful analysis of this largest single
tudy showed no discriminatory power of PET viability testing
o predicting patients who benefit from revascularization.
ff-pump CABG does not offset hemorrhage from
lopidogrel pretreatment. Clopidogrel had been given to
Figure 4 Survival Benefit for CABG Versus PCI by CAD Severity
These data derive from subtracting 17-year PCI from CABG Kaplan-Meier survival d
vival differences expressed as the extra patients projected to survive for each 100
ventional strategies is apparent in the low-severity and intermediate-severity CAD g
patients per 100 from revascularization by CABG compared with PCI by 3 years af
Adapted with permission from Smith et al. (7).81 (17.9%) of a total of 1,572 patients who underwent msolated off-pump CABG over a 30-month interval that
nded in June 2002 (12). These patients had either
eceived a 300-mg oral loading dose or a daily oral
egimen of 75 mg of clopidogrel within 7 days of CABG.
ultivariable logistic regression analysis examined the
ffect of clopidogrel on bleeding necessitating re-
peration, blood and transfusion rates, and operative
ortality. A propensity score matched pair analysis was
erformed for variables determined to be related to
erioperative hemorrhage. This analysis showed the co-
ort that received clopidogrel had a 3.9-fold increase (p
0.01) for re-exploration related to hemorrhage com-
ared with the matched cohort not on the drug. Need for
ny blood transfusion was 2 times greater in patients with
reoperative clopidogrel administration (p  0.01), and
he odds of receiving multiple blood units was increased
y 60% (p  0.02). Clopidogrel administration was found
o be associated with an increase in need for packed
ed blood cells (odds ratio 2.7, 95% confidence interval
.86 to 3.92, p  0.01) and platelet transfusions (odds
atio 2.3, 95% confidence interval 1.48 to 3.71, p  0.01).
he clopidogrel group did not have increased operative
ter adjustment for baseline clinical differences and propensity adjustment. Sur-
d by CABG compared with PCI. Little significant difference between the 2 inter-
However, the high-severity CAD group achieved a survival advantage of 6
procedure that remained through year 12. Abbreviations as in Figures 1 and 3.ata af
treate
roup.
ter theortality.
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May 8, 2007:1887–98 Year in Cardiovascular Surgeryurgery for Congenital Heart Disease
enchmarks for operative mortality for congenital heart
isease repair. The diversity of congenital heart presenta-
ions has made it difficult to risk-adjust outcomes of
Figure 5 Influence of Treatment Selection on Extension of Life
Additional months of survival added over 15 years of follow-up for the average
patient related to choice of treatment are depicted by severity of CAD as low
(black), intermediate (red), or high (white). *p  0.05. Med  medical ther-
apy; Revasc  revascularization; other abbreviations as in Figure 3. Reprinted
with permission from Smith et al. (7).
isk Score Predicting In-Hospital Death for PCI and CABG
Table 4 Risk Score Predicting In-Hospital Death for PCI and CA
Variable PCI Score
Age (yrs) 1 56–64
3 65–74
5 75
Female gender 1
Hemodynamic state 6 Unstable
9 Shock
Ejection fraction
0.20 3
0.20–0.29 2
0.30–0.39 0
Preprocedure myocardial infarction 9 24 h wit
7 6 h with
6 6–23 h wi
4 1–14 days
2 14 days
Peripheral artery disease 2
Renal failure requiring dialysis 4
4 Current HF
3 Past HF
3 Creatinine
3 Left maindapted with permission from Wu et al. (8) and Hannan et al. (9).
COPD  cardiac obstructive pulmonary disease; HF  heart failure; other abbreviations as in Table 3.perations for congenital heart disease to document ex-
ected operative mortality. The RACHS-1 (Risk Adjust-
ent for Congenital Heart Surgery-1) trial is increasingly
riteria CABG Score CABG Criteria
1 61–69
3 70–79
5 80
2
2 Unstable
5 Shock
4
3
2
t thrombosis 5 6 h
nt thrombosis 4 6–23 h
tent thrombosis 1 1–20 days
2
5
3 Prior heart operation
2 Calcified ascending aorta
mg/dl 1 COPD
CI Predicted Risk of In-Hospitalortality Associated With Individual Risk Scores*
Table 5 PCI Predicted Risk of In-HospitalMortality Associated With Individual Risk Scores*
Total Risk
Score
Rescaled
Predicted Risk (%)
Cumulative Percentage of Patients
With This Risk Score or Less (%)
0 0.04 8.30
1 0.06 19.47
2 0.08 26.27
3 0.11 39.29
4 0.15 48.58
5 0.20 60.81
6 0.28 70.24
7 0.38 78.46
8 0.52 84.39
9 0.72 88.07
10 0.98 91.98
11 1.34 93.98
12 1.83 95.84
13 2.50 97.12
14 3.39 98.10
15 4.60 98.64
16 6.19 99.10
17 8.29 99.36
18 11.00 99.55
19 14.43 99.68
20 18 100.00
The highest observed total risk score was 30 in 2003. Adapted with permission fromWu et al. (8).
PCI  percutaneous coronary intervention.BG
PCI C
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Year in Cardiovascular Surgery May 8, 2007:1887–98eing accepted as a system for consistent operative outcome
eporting after a multi-institutional report was made from
994 to 1996 data. All pediatric cardiac surgical procedures
erformed between 2001 and 2004 were categorized at 29
ongenital Heart Surgeon’s Society member institutions by
ACHS-1 category for reporting of in-hospital mortality
ates (13). The overall in-hospital mortality for the 12,672
Figure 6 Incidence of Emergency CABG After PCI
The annual percent of isolated CABG procedures in the Society of Thoracic Sur-
geons’ National Cardiac Database for which a PCI had been performed within
6 h and the subset also had a myocardial infarction within 24 h of CABG
declined from 1994 to 1999. Abbreviations as in Figure 1. Reprinted with per-
mission from Haan et al. (10).
ABG Predicted Risk of In-Hospitalortality Associated With Individual Risk Scores*
Table 6 CABG Predicted Risk of In-HospitalMortality Associated With Individual Risk Scores*
Total Risk
Score
Rescaled
Predicted Risk (%)
Cumulative Percentage of Patients
With This Risk Score or Less (%)
0 0.21 12.25
1 0.30 26.11
2 0.44 35.12
3 0.63 52.41
4 0.92 60.90
5 1.32 73.79
6 1.90 81.46
7 2.71 88.23
8 3.86 92.42
9 5.46 95.45
10 7.65 97.56
11 10.56 98.69
12 14.34 99.24
13 19.05 99.54
14 24.63 99.78
15 30.86 99.86
16 37.41 99.93
17 43.82 99.94
18 49.70 99.96
19 54.77 99.98
20 58 100.00
The highest observed total risk score was 21 in 2003. Adapted with permission fromWu et al. (8)
nd Hannan et al. (9).
CABG  coronary artery bypass graft.perations that could be placed into RACHS-1 categories
as 2.9%. The RACHS-1 classification functioned as a
ood discriminator of mortality with a C-statistic of 0.77.
ndividual center institutional total operative mortality
anged from 1.0% to 6.0%, and no center was consistently
etter or worse than another. Minimal variation was appar-
nt at the lowest risk categories, and categories 5 and 6 had
he least numbers of patients and the greatest variability in
ortality rate (Fig. 8). These data from high-quality centers
rovide a performance benchmark for the entire pediatric
ardiac surgical community.
Figure 7 Contribution of Failed PCI to Total CABG Mortality
These data depict the percent of all total isolated CABG mortality that occurred
in those patients who underwent surgery within 6 h of PCI (overall) and the
subset sustaining a myocardial infarction (MI) 24 h before CABG. Although
the incidence of urgent PCI decreased to 3 in 1,000 CABG operations, it still
contributed 10% of all CABG deaths. Abbreviations as in Figure 1. Reprinted
with permission from Haan et al. (10).
Figure 8 Influence of RACHS-1
Category on Operative Mortality
These institution-specific mortality rates by Risk Adjustment for Congenital
Heart Surgery (RACHS-1) category showed little diversity among the 3 lowest
levels of risk. Institution mortality rates seemed to vary more at higher
RACHS-1 categories as the complexity of the congenital disorder increased and
the numbers of patients who underwent surgery at each institution decreased.
Data analysis confirmed that this diversity was not statistically significant.
Reprinted with permission from Welke et al. (13).
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May 8, 2007:1887–98 Year in Cardiovascular Surgery-year mortality after heart operations in children.
alifornia hospital discharge data from 1989 to 1999 was
sed to assess death within 1 year after undergoing cardiac
urgery for all children18 years old (14). In-hospital death
ccurred in 1,505 (0.59%) of 25,402 pediatric cardiac
urgery cases. Death within the first year after discharge
ccurred in 148 (0.62%) of the 23,897 discharged children.
he rate of death in children discharged alive decreased
ith time after discharge, so there were 37 deaths within 30
ays (1.23/day), 44 deaths between 31 and 90 days (0.73/
ay), and 67 deaths between 91 and 365 days (0.24/day).
ogistic regression showed that young age was an important
isk factor for postdischarge death, with an odds ratio of 4.8
or neonates and 3.5 for infants when compared with
hildren older than 1 year. Operation performed was the
ajor risk factor. Gender, race/ethnicity, home income, and
ospital case volume did not relate significantly to postdis-
harge deaths.
schemic preconditioning in legs provides myocardial
rotection during cardiac surgery. Remote ischemic pre-
onditioning has been evaluated in children undergoing
epair of congenital heart defects (15). Four 5-min cycles of
ower limb ischemia and reperfusion were induced with a
lood pressure cuff within a 10-min interval of initiating
ardiopulmonary bypass for the cardiac operation. By ran-
om assignment, 17 children received the remote precon-
itioning protocol and 20 children served as control patients
ith a blood pressure cuff positioned on a leg without
nflation. Preoperative and postoperative measurements
ere made of lung mechanics, cytokines, and troponin I.
espite similar baseline clinical characteristics and operative
onduct, control patients had higher troponin I (p  0.04),
ore need for postoperative inotropic support (p  0.03),
nd higher airway resistance at 6 h postoperatively (p 
.009). This simple noninvasive technique shows sufficient
romise to warrant further study.
erum markers of mortality after cardiac surgery in
hildren. A retrospective cohort study of perioperative
linical and laboratory data from 1,001 consecutive children
ndergoing cardiac surgery during a 5-year period were
valuated by multivariable analysis to document the inde-
endent information that troponin T contributed to predic-
ion of death after pediatric cardiac surgery on cardiopul-
onary bypass (16). Troponin T and lactate level were the
trongest predictors of 30-day all-cause death with lactate
evel contributing the most information. A troponin T-1
evel 5.9 g/l on the first postoperative day predicted
eath with 95% specificity and 30% sensitivity.
BO-incompatible heart transplants perform well in
nfants. All 91 patients 18 months of age listed to
ndergo cardiac transplantation at a single institution from
992 to 2002 were evaluated for the influence of use of
BO blood group-incompatible donor hearts on patient
utcome (17). A strategy to accept ABO-incompatible
rgans was adopted in 1995. Higher waitlist status resulted
n greater mortality regardless of care strategy. However, for any waitlist status, more patients underwent transplan-
ation and fewer died using a strategy to accept ABO-
ncompatible organs. Parametric modeling of time-related
reedom from death or re-transplantation showed no signifi-
ant difference at 4 years for ABO-compatible or ABO-
ncompatible transplants. Using ABO-incompatible donor
earts for infant transplantation significantly improves the
ikelihood of transplantation and reduces waiting list mortality
hile not adversely altering outcomes after transplantation.
ercutaneous compares favorably with operative atrial
eptal defect closure. Short-term outcomes were com-
ared on 533 patients who underwent surgical and 751
atients who underwent percutaneous atrial septal defect
losure at a single institution without procedure deaths (18).
ultivariable logistic regression analysis showed that sur-
ery was an independent predictor of total and major
omplications. However, the surgical population had more
omplex defects, and 16 patients had major complications
rom the percutaneous procedure that required operation.
VAD bridge to transplant improves in children. A
ulti-institutional database was used to analyze outcomes
f 99 patients listed for ventricular assist devices by waiting
or heart transplant between January 1993 and December
003 (19). Diagnoses were cardiomyopathy in 78% and
ongenital heart disease in 22%. Successful bridge to trans-
lant was more common in the modern era (Fig. 9). The
-year survival was similar to that of patients who under-
ent heart transplantation without requiring ventricular
ssist device placement.
urgery for Cardiac Valve Disease
oninvasive screening effectively identifies CAD in
atients scheduled for heart valve operations. From a
onsecutive group of 145 patients scheduled for cardiac
alve surgery, 97 patients were eligible and 70 consented to
ndergo 64-slice computed tomography coronary angiogra-
hy for assessment of CAD and comparison with an
xisting quantitative coronary angiogram (20). The question
ddressed was whether computed tomography coronary
ngiography could provide adequate characterization of
AD to obviate the need for coronary angiography before
alve surgery. Twenty-six (37%) of 70 patients had previous
yocardial infarction or angina. The prevalence of signifi-
ant CAD defined as having at least one 50% stenosis per
atient was 26%, and the test was 100% sensitive for 50%
tenosis on the quantitative coronary angiogram. This non-
nvasive imaging modality would seem to be a useful
creening test for significant CAD in patients with planned
ardiac valve surgery.
tructured care without operation is acceptable in
symptomatic patients with severe mitral regurgitation. A
otal of 132 consecutive asymptomatic patients with severe
egenerative mitral regurgitation were prospectively fol-
owed up for a median of 69.2 months (21). Serial clinical
nd echocardiographic examinations were conducted at least
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Year in Cardiovascular Surgery May 8, 2007:1887–98very 12 months, and patients were referred to surgery at the
nset of mild symptoms. Asymptomatic patients also were
eferred on development of 1 or more of the following
riteria: left ventricular end-systolic diameter 45 ml or
nd-systolic diameter index 25 ml/m2, fractional shorten-
ng 0.32 or ejection fraction 0.60, systolic pulmonary
ressure 50 mm Hg, or recurrent atrial fibrillation. Pa-
ients were continuously followed up after surgery to mon-
tor the late results of the preoperative evaluation strategy.
ollow-up information was complete for 129 (98%) of the
32 consecutive asymptomatic patients entered into the
tudy. During follow-up, 8 deaths occurred, and 38 patients
eveloped criteria for operation. There was no operative
ortality. This approach of systematic patient monitoring
ith watchful waiting provides a useful population to
ompare with similar patients who also would be at low risk
or mitral valve repair.
ge and not valve type is the strongest predictor of
ortality after cardiac valve replacement. A meta-
nalysis was performed on overall mortality after aortic
alve replacement on information from 32 articles pub-
ished from 1989 to 2004 that reported operations
erformed between 1975 and 2002 with a maximum
ollow-up of at least 10 years (22). The 17,439 patients
ere followed up for 101,819 patient-years, and 5,170
eaths (936 early and 4,234 late) occurred. The mean
atient age was 58 years in the 15 articles describing
echanical valve use and 69 years in the 23 articles
escribing biological valve use. For mechanical valves, the
verall death rate was 3.99%/patient-year, and for bio-
ogical valves the overall death rate was higher at 6.33%/
atient-year. Median age was strongly related to death
Figure 9 Outcomes of Expanded LVAD Use in Children
These competing analysis outcomes show fewer patients supported by left ventric
use, 1993 to 1999, n  39, compared with (B) the recent era of expanded LVAD
reducing the proportion of patients waiting for transplants and those dying while wate (p  0.0001) (Fig. 10). When corrected for age inhe regression model, variables that retained a significant
ffect on death rate included New York Heart Associa-
ion functional classes III and IV, which increased, and
ortic regurgitation, which decreased mortality. After
orrection for the impact of these factors, valve type did
ot have an independent influence on mortality. This
nalysis with patient summary data and not individual
atient data as the unit of analysis did not permit analysis
sist device (LVAD) to have received a transplant during (A) the early era of LVAD
000 to 2003, n  50, when more transplantations were performed, thereby
Reprinted with permission from Blume et al. (19).
Figure 10 Death Rate and Age Reported
for Mechanical and Bioprosthetic Valves
The total death rate is compared with the mean age of patients in each of 15
series reporting mechanical (filled squares) and 23 series reporting biopros-
thetic (open squares) valves in relation to the mean age of patients included in
each series. The areas of squares are proportional to total patient years of
follow-up. Patients in series receiving bioprosthetic valves had an older average
age, but the relationship between average reported age and death rate of the
reporting series seems to have a similar relationship for mechanical and bio-
prosthetic valves. Reprinted with permission from Lund and Bland (22).ular as
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May 8, 2007:1887–98 Year in Cardiovascular Surgeryf an interaction term between age and valve type. These
ata suggest that number of years lived may not be as
mportant a determinant in valve choice as combinations
f other specific risk factors that interface with age. For
xample, risk of bioprosthetic valve degeneration would
e especially troublesome in young otherwise healthy
atients, but also in older patients with a long life
xpectancy.
ricuspid valve repair provides better outcomes than
eplacement. Outcomes of tricuspid valve repair were
ompared with valve replacement in 250 patients with
rganic tricuspid valve disease at a single institution from
979 to 2003 (23). Tricuspid repair was performed in 178
71%). Tricuspid replacement in 72 (29%) was done
sing a bioprosthetic valve in 54 and a mechanical valve
n 18 patients. Cox regression analysis showed tricuspid
alve replacement to be an independent predictor of
ower event-free survival (hazard ratio 2.0, 95% confi-
ence interval 1.1 to 3.6, p  0.02). Echocardiography
howed more moderate-to-severe tricuspid regurgitation
n patients undergoing repair, but no difference in func-
ional class or re-operation rates over a mean follow-up
ime of 5.2  4.1 years.
trial Fibrillation in Cardiac Surgical Patients
eft atrial volume and age predict atrial fibrillation after
eart operations. The power of clinical and transthoracic
chocardiogram variables to predict postoperative atrial
brillation was assessed in 205 patients undergoing
ardiac surgery (24). Multivariable modeling of prospec-
ively acquired data showed left atrial volume and age to
e the 2 significant predictors of postoperative atrial
brillation that occurred in 84 (41.4%) of the 205
atients a median of 1.8 days after cardiac surgery.
tratification of patients by age and left atrial volume
uggests special attention should be directed to preven-
ion and treatment of postoperative atrial fibrillation in
atients who are older than age 65 years and have a left
trial diameter 32 mm Hg/m2 (Fig. 11).
torvastatin reduces atrial fibrillation after cardiac sur-
ery. Seven days before a planned elective cardiac operation
equiring cardiopulmonary bypass, 200 patients were ran-
omized to receive atorvastatin (40 mg/day, n  101) or
lacebo (n 99) (25). Atorvastatin reduced the incidence of
ostoperative atrial fibrillation compared with placebo (95%
s. 57%, p  0.003). Therefore, the length of stay was
onger for patients in the placebo compared with those in
he atorvastatin arm (6.9  1.4 days vs. 6.3  1.2 days, p 
.001). Multivariable analysis showed that atorvastatin re-
uced the risk of atrial fibrillation (odds ratio 0.39, 95%
onfidence interval 0.18 to 0.85, p 0.017), whereas a high
ostoperative C-reactive protein increased risk (odds ratio
.0, 95% confidence interval 1.2 to 7.0, p  0.01). Major
dverse cerebrovascular events at 30 days did not differ
etween the 2 groups. (tatus Report of Major Ongoing Randomized
linical Trials in Cardiac Surgical Patients
utcomes After Myocardial Revascularization: On and
ff Cardiopulmonary Bypass (ROOBY) trial. Sponsor:
eterans Affairs Cooperative Study.
Principal investigator: Frederick L. Grover, MD
frederick.grover@uchsc.edu).
Hypothesis: In properly selected patients, 30-day and
-year mortality and morbidity are equivalent when CABG
s conducted with or without using cardiopulmonary bypass.
Enrollment: 2,100 of 2,200 patients enrolled by 17 U.S.
eterans Affairs hospitals.
TICH trial. Sponsor: National Institutes of Health.
Principal investigator: Robert H. Jones, MD (jones060@
c.duke.edu).
Hypothesis 1: CABG combined with intensive medical
herapy improves long-term survival compared with inten-
ive medical therapy alone in 1,000 patients with LVEF
0.35 and CAD amenable to CABG.
Hypothesis 1 enrollment: 1,039 of 1,200 patients enrolled
y 99 sites worldwide. Completion expected June 2007.
Hypothesis 2: Adding surgical ventricular restoration to
ABG and intensive medical therapy improves survival free
f cardiac hospitalization in 1,000 patients with LVEF
0.35, CAD amenable to CABG, and dominant anterior
kinesia or dyskinesia.
Hypothesis 2 enrollment: 1,000 patients completed Jan-
ary 24, 2006, by 96 sites worldwide. Primary outcome
eport expected in 2008.
uture Revascularization Evaluation in Patients with
iabetes Mellitus: Optimal Management of Multivessel
isease (FREEDOM) trial. Sponsor: National Heart,
ung, and Blood Institute.
Principal investigator: Valentin Fuster, MD, PhD
Figure 11 Left Atrial Volume and Age Influence
on Atrial Fibrillation After Cardiac Surgery
Survival free from postoperative atrial fibrillation is stratified by left atrial vol-
ume and age over the first 7 days after cardiac surgery. Reprinted with permis-
sion from Osranek et al. (24).valetin.fuster@mssm.edu).
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Year in Cardiovascular Surgery May 8, 2007:1887–98Hypothesis: In 2,400 diabetic patients with multivessel
isease amenable to CABG and PCI and indication for
evascularization, either CABG or PCI will be superior in
reventing death, nonfatal myocardial infarction, and
troke.
Enrollment: 537 of 2,400 patients enrolled. Activation
ompleted at 117 clinical sites.
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